Barriers and Strategies to Optimize the Use of Glucagon-Like Peptide 1 Receptor Agonists in People with Type 2 Diabetes and High Cardiovascular Risk or Established Cardiovascular Disease: A Delphi Consensus in Spain

1. Botana López, M.
2. Camafort Babkowski, M.
3. Campuzano Ruiz, R.
4. Cebrián Cuenca, A.
5. Gargallo Fernández, M.
6. David de Paz, H.
7. Redondo-Antón, J.
8. Artime, E.
9. Díaz-Cerezo, S.
10. Rubio de Santos, M.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1007/S12325-024-02938-2 GOOGLE SCHOLAR lock_openOpen access editor

Data source: Scopus